)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Concord Biotech (CONCORDBIO) investor relations material
Concord Biotech Q2 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 25/26 earnings summary14 Nov, 2025
Executive summary
Q2 FY2026 revenue was INR 247 crore, down 20% year-over-year, due to regulatory delays, Middle East tender deferment, and US tariff uncertainties, but management expects a strong recovery in H2 as deferred shipments resume.
Multiple regulatory approvals (US FDA, EU GMP, Russian GMP, NAFDAC) were secured, supporting global market expansion and business continuity.
Strategic initiatives included US FDA approval for teriflunomide tablets, incorporation of Stelon Biotech for US market operations, and investment in Celliimune Biotech for CAR-T cell therapy development.
Board approved acquisition of 100% equity in Celliimune Biotech Private Limited and investment up to Rs. 10 Crores in a captive hybrid solar power project for the Limbasi Plant.
Advanced discussions with innovator companies for API supplies and increased second source qualification initiatives signal future growth opportunities.
Financial highlights
Q2 FY2026 revenue was INR 247 crore (₹247.1 Cr), down from INR 310 crore (₹310.2 Cr) in Q2 FY2025; H1 FY2026 revenue was INR 451 crore (₹451.1 Cr), down from INR 526 crore in H1 FY2025.
Q2 FY2026 EBITDA was INR 88 crore (₹88.5 Cr, margin 35.8%), with H1 EBITDA at INR 150 crore (₹149.9 Cr, margin 33.2%); Q2 EBITDA margin adjusted to 41% excluding injectable facility startup costs.
Q2 FY2026 PAT was INR 63 crore (₹63.1 Cr, margin 25.5%); H1 PAT was INR 107 crore (₹107.1 Cr, margin 23.7%).
Gross profit margin improved to 80.2% in Q2 FY2026 from 75.4% in Q2 FY2025.
Standalone revenue from operations for Q2 FY2026 was Rs. 24,705.75 lakhs, with standalone net profit at Rs. 6,289.63 lakhs.
Outlook and guidance
Management anticipates H2 FY2026 growth to surpass H2 FY2025, with deferred revenues expected to be recovered as regulatory and geopolitical issues resolve.
Long-term confidence in achieving a 25% CAGR remains, supported by new facilities and product mix.
Injectable facility expected to ramp up, contributing positively to margins and revenue in the coming quarters.
Two pipeline products are expected to be commercialized within the next six months.
The company is expanding through acquisitions and investments in renewable energy, indicating a focus on growth and sustainability.
CAR-T cell therapy: India market strategy
Injectable facility: path to positive contribution
Immunosuppressant revenue share: 2-3 year outlook
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Concord Biotech earnings date
Q3 25/2613 Feb, 2026
Next Concord Biotech earnings date
Q3 25/2613 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage